Key facts
- This page summarizes Ansbert Gadicke's Form 4 filing for Werewolf Therapeutics, Inc. (HOWL).
- 4 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 30 Apr 2025, 16:08.
Ansbert Gadicke - 27 Mar 2025 Form 4 Insider Report for Werewolf Therapeutics, Inc. (HOWL)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- HOWL
- Reported as of
- 27 Mar 2025
- Net transaction value
- -$26.73
- SEC form
- 4
- Accepted by SEC
- 30 Apr 2025, 16:08:50 UTC
- Prior SEC filing
- 05 Jun 2023
- Next SEC filing
- 15 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ansbert Gadicke
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ansbert Gadicke filed Form 4 for Werewolf Therapeutics, Inc. (HOWL) on 30 Apr 2025.
Change
- Previous filing in this sequence was filed on 05 Jun 2023.
- Current net transaction value: -$26.73.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
HOWL
transaction
Common Stock
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- $4,579
- Shares
- +50,873
- Change %
- +0.76%
- Price
- $0.0900
- Shares after
- 6,723,056
- Date
- 27 Mar 2025
- Ownership
- See Footnote
- Footnotes
- F1, F2, F3
HOWL
transaction
Common Stock
Sale
- Transaction value
- $4,605
- Shares
- -4,386
- Change %
- -0.07%
- Price
- $1.05
- Shares after
- 6,718,670
- Date
- 27 Mar 2025
- Ownership
- See Footnote
- Footnotes
- F1, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
HOWL
transaction
Derivative
Warrant (Right to Buy)
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- $0
- Shares
- -8,031
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 27 Mar 2025
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 8,031
- Exercise price
- $0.0900
- Footnotes
- F1, F5, F6
HOWL
transaction
Derivative
Warrant (Right to Buy)
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- $0
- Shares
- -42,842
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 27 Mar 2025
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 42,842
- Exercise price
- $0.0900
- Footnotes
- F1, F5, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 7 footnotes
Footnote F1
On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 50,873 shares of the Company's Common Stock for $0.09 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 4,386 of the warrant shares to pay the exercise price and issuing the remaining 46,487 shares.
Footnote F2
The shares are held as follows: 461,408 by MPM Asset Management LLC ("AM LLC"), 2,915,905 by MPM BioVentures 2014, L.P. ("BV 2014"), 194,486 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 100,365 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 640,121 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 2,410,771 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Footnote F3
MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Footnote F4
The shares are held as follows: 461,408 by AM LLC, 2,914,123 by BV 2014, 194,367 by BV 2014(B), 100,303 by AM BV2014, 639,659 by MPM OIF and 2,408,810 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Footnote F5
Immediately exercisable.
Footnote F6
The warrants were held as follows: 3,647 by BV 2014, 243 by BV 2014(B), 125 by AM BV 2014 and 4,016 by UBS Oncology.
Footnote F7
The warrants were held as follows: 17,023 by BV 2014, 1,135 by BV 2014(B), 585 by AM BV 2014, 5,355 by MPM OIF and 18,744 by UBS Oncology.